I agree that this site is using cookies. You can find further informations here.
X
Vadrevu, Krishna Mohan
156  results:
Search for persons X
?
1

Overstated conclusions of a non-inferiority trial testing i..:

Vadrevu, Krishna Mohan
The Lancet Regional Health - Southeast Asia.  12 (2023)  - p. 100198 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Phase III Pivotal comparative clinical trial of intranasal ..:

Singh, Chandramani ; Verma, Savita ; Reddy, Prabhakar...
npj Vaccines.  8 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
3

Phase III randomized clinical studies to evaluate the immun..:

P, Krishna Kumari ; Chiteti, Siddharth Reddy ; Aileni, Vinay K....
Human Vaccines & Immunotherapeutics.  19 (2023)  3 - p. , 2023
Link: https://doi.org/10.1080/..
 
?
4

Safety, immunogenicity and non-interference of concomitant ..:

Vadrevu, Krishna Mohan ; Dugyala, Raju ; Mahantashetti, Niranjana Shamulinga...
Human Vaccines & Immunotherapeutics.  18 (2022)  7 - p. , 2022
Link: https://doi.org/10.1080/..
 
?
5

Booster dose of the inactivated COVID-19 vaccine BBV152 (Co..:

Deshpande, Gururaj Rao ; Yadav, Pragya D ; Abraham, Priya...
Journal of Travel Medicine.  29 (2022)  3 - p. , 2022
Link: https://doi.org/10.1093/..
 
?
6

Persistence of immunity and impact of third dose of inactiv..:

Vadrevu, Krishna Mohan ; Ganneru, Brunda ; Reddy, Siddharth...
Scientific Reports.  12 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
7

Protective efficacy of COVAXIN® against Delta and Omicron v..:

Yadav, Pragya D. ; Mohandas, Sreelekshmy ; Shete, Anita...
iScience.  25 (2022)  10 - p. 105178 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Preclinical evaluation of safety and immunogenicity of a pr..:

Sunagar, Raju ; Prasad, Sai D. ; Ella, Raches.
Frontiers in Immunology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
9

Persisting antibody responses to Vi polysaccharide–tetanus ..:

Vadrevu, Krishna Mohan ; Raju, Dugyala ; Rani, Sandhya...
Vaccine.  39 (2021)  45 - p. 6682-6690 , 2021
Link: https://doi.org/10.1016/..
 
?
10

A multi-centre, post-marketing surveillance study of Vi pol..:

Reddy, Raghu ; Reddy, Bhargav ; Sarangi, Vamshi...
Human Vaccines & Immunotherapeutics.  18 (2021)  1 - p. , 2021
Link: https://doi.org/10.1080/..
 
?
11

Immunogenicity and protective efficacy of BBV152, whole vir..:

Mohandas, Sreelekshmy ; Yadav, Pragya D. ; Shete-Aich, Anita...
iScience.  24 (2021)  2 - p. 102054 , 2021
Link: https://doi.org/10.1016/..
 
?
12

Th1 skewed immune response of whole virion inactivated SARS..:

Ganneru, Brunda ; Jogdand, Harsh ; Daram, Vijaya Kumar...
iScience.  24 (2021)  4 - p. 102298 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neu..:

Sapkal, Gajanan N ; Yadav, Pragya D ; Ella, Raches...
Journal of Travel Medicine.  28 (2021)  4 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
14

Efficacy, safety, and lot-to-lot immunogenicity of an inact..:

Ella, Raches ; Reddy, Siddarth ; Blackwelder, William...
The Lancet.  398 (2021)  10317 - p. 2173-2184 , 2021
Link: https://doi.org/10.1016/..
 
?
15

A randomized, open-labelled, non-inferiority phase 4 clinic..:

Ella, Raches ; Babji, Sudhir ; Ciarlet, Max..
Vaccine.  37 (2019)  31 - p. 4407-4413 , 2019
Link: https://doi.org/10.1016/..
 
1-15